Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

MLA

Bernies van der Hiel, et al. “Vemurafenib plus Cobimetinib in Unresectable Stage IIIc or Stage IV Melanoma: Response Monitoring and Resistance Prediction with Positron Emission Tomography and Tumor Characteristics (REPOSIT): Study Protocol of a Phase II, Open-Label, Multicenter Study.” BMC Cancer, vol. 17, no. 1, Sept. 2017, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12885-017-3626-5.

APA

Bernies van der Hiel, John B.A.G. Haanen, Marcel P.M. Stokkel, Daniel S. Peeper, Connie R. Jimenez, Jos H. Beijnen, Bart A. van de Wiel, Ronald Boellaard, Alfons J.M. van den Eertwegh, & REPOSIT study group. (2017). Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer, 17(1), 1–13. https://doi.org/10.1186/s12885-017-3626-5

Chicago

Bernies van der Hiel, John B.A.G. Haanen, Marcel P.M. Stokkel, Daniel S. Peeper, Connie R. Jimenez, Jos H. Beijnen, Bart A. van de Wiel, Ronald Boellaard, Alfons J.M. van den Eertwegh, and REPOSIT study group. 2017. “Vemurafenib plus Cobimetinib in Unresectable Stage IIIc or Stage IV Melanoma: Response Monitoring and Resistance Prediction with Positron Emission Tomography and Tumor Characteristics (REPOSIT): Study Protocol of a Phase II, Open-Label, Multicenter Study.” BMC Cancer 17 (1): 1–13. doi:10.1186/s12885-017-3626-5.